Trials / Completed
CompletedNCT05674929
An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder
An Open-Label, Phase 2a Single Dose Study in Patients With Alcohol Use Disorder
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Beckley Psytech Limited · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
An open-label, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamic effects of a single intranasal dose of BPL-003 combined with relapse prevention psychological support, to explore the potential effects on alcohol use and related symptoms in patients with Alcohol Use Disorder.
Detailed description
Approximately 12 eligible participants will be receive a single dose of BPL-003, given intranasally, with 12 weeks of follow-up assessments. Psychological support will be given before, during and after dosing
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BPL-003 | A single dose administered intranasally |
Timeline
- Start date
- 2023-05-30
- Primary completion
- 2024-10-02
- Completion
- 2024-10-02
- First posted
- 2023-01-09
- Last updated
- 2025-08-14
Locations
2 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05674929. Inclusion in this directory is not an endorsement.